Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines.

Christian Jakob, MD, Jan Sterz, MD, Ivana von Metzler, MD, Ulrike Kuckelkorn, PhD, Hannes A. Braun, PhD, Susanne Rötzer, MD, Martin Kaiser, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD

Blood (2007) 110 (11): 1401.

https://doi.org/10.1182/blood.V110.11.1401.1401

Published: 2007

Journal Articles

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

Christian Jakob, MD, Peter Liebisch, MD, Karl Egerer, MD, Jan Sterz, MD, Martin Kaiser, MD, Susanne Rötzer, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Claudia Fleissner, MD, Peter M. Kloetzel, PhD, Evangelos Terpos, MD, Orhan Sezer, MD

Blood (2007) 110 (11): 1475.

https://doi.org/10.1182/blood.V110.11.1475.1475

Published: 2007

Journal Articles

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Jan Sterz, MD, Christian Jakob, MD, Ulrike Kuckelkorn, PhD, Hannes A. Braun, PhD, Martin Kaiser, MD, Claudia Fleissner, MD, Lorenz Kleeberg, MD, Ulrike Heider, MD, Kurt Possinger, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD, Ivana Zavrski, MD

Blood (2006) 108 (11): 3475.

https://doi.org/10.1182/blood.V108.11.3475.3475

Published: 2006

Journal Articles

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Christian Jakob, Karl Egerer, Peter Liebisch, Seval Türkmen, Ivana Zavrski, Ulrike Kuckelkorn, Ulrike Heider, Martin Kaiser, Claudia Fleissner, Jan Sterz, Lorenz Kleeberg, Eugen Feist, Gerd-R. Burmester, Peter-M. Kloetzel, Orhan Sezer

Blood (2006) 109 (5): 2100–2105.

https://doi.org/10.1182/blood-2006-04-016360

Published: 2006

Journal Articles

Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma.

Christian Jakob, MD, Karl Egerer, PhD, Eugen Feist, MD, Ivana Zavrski, MD, Jan Eucker, MD, Ulrike Heider, MD, Gerd Burmester, MD, Kurt Possinger, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD

Blood (2004) 104 (11): 1486.

https://doi.org/10.1182/blood.V104.11.1486.1486

Published: 2004

NARROW

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines.

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines.

The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1–3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma.

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only